This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Isaacs, J. T.

Relationship between Tumor Size and Curability of Prostatic Cancer by Combined Chemo-Hormonal Therapy in Rats¹

Johns Hopkins Oncology Center and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Nearly all men with metastatic prostatic cancer respond to androgen ablation, demonstrating that at least a portion of their cancer cells are androgen responsive. Unfortunately, however, individual prostatic cancers contain clones of androgen-independent, in addition to androgen-responsive, cancer cells. Due to this tumor cell heterogeneity, essentially all patients treated with androgen ablation alone eventually relapse to a state unresponsive to further antiandrogen therapy; cures are rarely produced. To produce cures, additional nonhormonal therapy targeted at the androgen-independent prostatic cancer cells within the patient should be combined with androgen ablation targeted at the androgen-dependent cancer cells.

The validity of such combined chemo-hormonal therapy was tested using, as the experimental model, two members of the Dunning system of serially transplantable rat prostatic cancers. Specifically the slow growing, well differentiated H and the fast growing, poorly differentiated G Dunning sublines were used, since these cover the clinical extremes observed for human prostatic cancers. The chemotherapeutic agent used in combination with surgical androgen ablation (i.e., castration) in these studies was Cytoxan. These studies demonstrate that for both the H and G cancer-bearing rats, the mean survival following combined chemohormonal therapy was increased above that found for castrate or Cytoxan when either was used as monotherapy. In addition, an inverse relationship between tumor size at the time of initiation of therapy and the ability of the combined chemo-hormonal therapy to cure animal bearing either the H or G sublines was demonstrated. Such combined chemo-hormonal therapy could only cure a proportion (i.e., 30–40%) of H or G tumor-bearing animals if initiated when the tumor was 0.2 cm³ in size. In contrast, if the tumor was 1–2 cm³ in starting size when the chemohormonal therapy was initiated, no animal was cured. Neither of the monotherapies (i.e., castrates or Cytoxan alone) could cure any animals regardless of the starting size.

¹ This work was supported by Department of Health and Human Services Grant CA-15416.

Received 5/ 8/89. Revised 8/15/89. Accepted 8/21/89.

This article has been cited by other articles:

				D. J. George, C. A. Dionne, J. Jani, T. Angeles, C. Murakata, J. Lamb, and J. T. Isaacs Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Res., May 1, 1999; 59(10): 2395 - 2401. [Abstract] [Full Text] [PDF]